EUVIMEDEUVIMED entdecken
Leitlinie

Challenges in the nonclinical safety evaluation of biotechnology-derived pharmaceuticals and perspectives for revision of the ICH S6 guideline based on analysis of approved products in Japan

Takuya NISHIMURA, Yusuke OKUBO, Misaki NAOTA, Yui SUZUKI, Mutsumi SUZUKI, Kazuto WATANABE, Takahiro NAKAZAWA, Makiko KUWAGATA, Hiroshi ONODERA, Yoko HIRABAYASHI

Translational and Regulatory Sciences · 2026 · 8 (2) · 7-14

DOI: 10.33611/trs.2026-002 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Translational and Regulatory Sciences, 2026. Verfasst von Takuya NISHIMURA und 9 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

NISHIMURA, T., OKUBO, Y., NAOTA, M., SUZUKI, Y., SUZUKI, M., WATANABE, K., NAKAZAWA, T., KUWAGATA, M., ONODERA, H., & HIRABAYASHI, Y. (2026). Challenges in the nonclinical safety evaluation of biotechnology-derived pharmaceuticals and perspectives for revision of the ICH S6 guideline based on analysis of approved products in Japan. Translational and Regulatory Sciences, 8(2), 7-14. https://doi.org/10.33611/trs.2026-002

Vancouver

NISHIMURA T, OKUBO Y, NAOTA M, SUZUKI Y, SUZUKI M, WATANABE K, et al. Challenges in the nonclinical safety evaluation of biotechnology-derived pharmaceuticals and perspectives for revision of the ICH S6 guideline based on analysis of approved products in Japan. Translational and Regulatory Sciences. 2026;8(2):7-14. doi:10.33611/trs.2026-002

BibTeX
@article{NISHIMURA2026,
  author = {NISHIMURA, Takuya and OKUBO, Yusuke and NAOTA, Misaki and SUZUKI, Yui and SUZUKI, Mutsumi and WATANABE, Kazuto and NAKAZAWA, Takahiro and KUWAGATA, Makiko and ONODERA, Hiroshi and HIRABAYASHI, Yoko},
  title = {Challenges in the nonclinical safety evaluation of biotechnology-derived pharmaceuticals and perspectives for revision of the ICH S6 guideline based on analysis of approved products in Japan},
  journal = {Translational and Regulatory Sciences},
  year = {2026},
  volume = {8},
  number = {2},
  pages = {7--14},
  doi = {10.33611/trs.2026-002}
}
Kostenlos starten →